Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
41 hedge funds and large institutions have $331M invested in Oyster Point Pharma, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
63.52% more ownership
Funds ownership: 0% → 63.52% (+64%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$104M |
| 2 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
+$18.2M |
| 3 |
VM
VV Manager
Boston,
Massachusetts
|
+$16.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.29M |
| 5 |
BlackRock
New York
|
+$6.61M |
Top Sellers
OYST Hedge Fund Activity: Q4 2019 in Review
41 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q4 2019, worth a combined $331M.
Buyers outnumbered sellers: 41 funds opened new OYST positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $104M.
- 41 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $331M of Oyster Point Pharma, Inc. Common Stock stock for Q4 2019.
- 41 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q4 2019 and 0 closed out, a net change of +41 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q4 2019 was NEA Management Company, an estimated $104M added.
Based on aggregated 13F filings for Q4 2019.